Ribociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, has received authorization for the treatment of HR+ and HER2- breast cancer patients 35, and it is revealed to be one of the most sensitive medications for the HG. Here, ERBB2 is linked to breast cancer.